Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by Peninsula Technology Assessment Group (PenTAG):

  • Bond M, Rogers G, Peters J et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of NICE technology appraisal guidance 111): a systematic review and economic model, June 2010.

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I, II and III were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I) Manufacturers/sponsors:

  • Eisai/ Pfizer

  • Lundbeck

  • Novartis

  • Shire

II) Professional/specialist and patient/carer groups:

  • Alzheimer's Society

  • Brunelcare

  • The Neurological Alliance

  • Association of British Neurologists

  • British Geriatrics Society

  • Royal College

  • Royal of Physicians

  • Royal of Psychiatrists

III) Other consultees:

  • Department of Health

  • NHS Islington

  • NHS West Kent

  • Welsh Assembly Government

IV) Commentator organisations (without the right of appeal):

  • NHS Quality Improvement Scotland

  • Eisai/Pfizer

  • Lundbeck

  • Novartis

  • Shire

  • Institute for Ageing and Health

  • Research Institute for the Care of Older People

  • Peninsula Technology Assessment Group, University

  • National Institute for Health Research Health Technology Assessment Programme

  • National Collaborating Centre for Mental Health

B. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of technology appraisal guidance 111) by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Anthony Bayer, Senior Lecturer in Geriatric Medicine, nominated by British Geriatrics Society – clinical specialist

  • Dr Peter Connelly, Consultant Old Age Psychiatrist, nominated by NHS Quality Improvement Scotland – clinical specialist

  • Andrew Chidgey, Head of Policy and Public Affairs, Alzheimer's Society, nominated by Alzheimer's Society – patient expert

  • Chris Hill, nominated by Alzheimer's society – patient expert

  • Henry Simmons, Chief Executive, Alzheimer Scotland, nominated by NHS Quality Improvement Scotland – patient expert

C. The following individuals were nominated as NHS Commissioning experts by the selected NHS Trust allocated to this appraisal. They gave their expert/NHS commissioning personal view on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Edwina Affie, Assistant Director Public Health, NHS Islington, selected by NHS Islington – NHS Commissioning expert

  • Amelia Stecher, Assistant Director of Care Standards/Acting IFR Lead, NHS West Kent, selected by NHS West Kent – NHS Commissioning expert

D. Representatives from the following manufacturers/sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Eisai/ Pfizer

  • Lundbeck

  • Novartis

  • Shire

  • National Institute for Health and Care Excellence (NICE)